Clinical Trials Logo

Clinical Trial Details — Status: Unknown status

Administrative data

NCT number NCT00995397
Other study ID # ERP 976-08
Secondary ID
Status Unknown status
Phase Phase 3
First received October 14, 2009
Last updated October 20, 2009

Study information

Verified date October 2009
Source Mantecorp Industria Quimica e Farmaceutica Ltd.
Contact Sérgio Schalka, MD
Phone +551136811334
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Insect bite related symptoms (pruritus and papules) are caused by the release of histamine by mast cells in the skin. Topical anti-histaminics can be used to promote relief of these symptoms. Dexchlorpheniramine maleate 1% cream is a topical anti-histaminic formulation approved by ANVISA in Brazil for the relief of skin irritation and allergies, including the ones caused by insect bites. The aim of the present study is to demonstrate non-inferiority of a new pharmacological preparation of dexchlorpheniramine maleate (1% lotion) with the standard preparation (1% cream) for the relief of insect bite related symptoms and to demonstrate the safety of both preparations.


Recruitment information / eligibility

Status Unknown status
Enrollment 30
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender All
Age group 2 Years to 60 Years
Eligibility Inclusion Criteria:

- Presence of papules resulting from insect bites within the last 72 hours

- Presence of symmetric lesions to compare one side to the other

- Compliance of the subject to the treatment protocol

- Agreement with the terms of the informed consent by the participants or their legal guardians when younger than 18 years old

Exclusion Criteria:

- Pregnancy or risk of pregnancy

- Lactation

- Use of topical or systemic anti-inflammatory, anti-histaminics or immunosuppressive drugs within the last 48 hours prior to the study

- History of atopy or allergic diseases

- History of allergy of any component of the formulations

- Other conditions considered by the investigator as reasonable for non-eligibility

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Dexchlorpheniramine 1% lotion
Small amount applied over the lesion twice a day for 7 days.
Dexchlorpheniramine 1% cream
Small amount applied over the lesion twice a day for 7 days.

Locations

Country Name City State
Brazil Medcin Instituto da Pele Ltda. Osasco São Paulo

Sponsors (1)

Lead Sponsor Collaborator
Mantecorp Industria Quimica e Farmaceutica Ltd.

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pruritus intensity at insect bite site, evaluated with a 10 point Visual Analogic Scale (VAS) 7 days
Secondary Composite clinical evaluation of erythema, pruritus and papule formation, performed by the investigator using a 4-point scale for each one of the parameters (absent, mild, moderate, intense). This evaluation constitutes the Insect Bite Score. 7 days
See also
  Status Clinical Trial Phase
Completed NCT03999970 - A Clinical Study to Develop an Uninfected Sand Fly Biting Protocol N/A
Completed NCT04512742 - A Clinical Study to Develop a Controlled Human Infection Model Using Leishmania Major-infected Sand Flies N/A
Active, not recruiting NCT00825214 - Evaluation of Zapperclick Device for Relief From Mosquito Bites Phase 3
Not yet recruiting NCT01233934 - Comparative Study of Two Forms of Topical Dexchlorpheniramine Maleate (Cream Versus Gel) for Insect Bites Phase 3
Terminated NCT03619746 - Point-of-Care Ultrasound Educational Initiative for Insect Bites N/A